MedXCell SA selected to participate in the sixth edition of the pre-IPO program TechShare organized by Euronext

Montreux, Switzerland | January 21, 2021 – MedXCell SA, a Swiss biotech company dedicated to transforming healthcare through the development and production of affordable and accessible new therapies utilizing the unique powers of living cells, announced its selection for the pan-European pre-IPO program TechShare organized by Euronext, the largest stock exchange market in Europe.

About TechShare

Euronext launches this January the sixth edition of TechShare, the only European program that supports and guides young ventures with a mature corporate profile for their IPO preparation. Furthermore, it builds a network between dedicated strategy experts and fast-growing companies. Their mission is to help these promising start-ups understand the role and criteria of capital markets and learn how to implement it into their business model.

All technological sectors are represented this year, with a particular interest in biotechs, medtechs, and e-commerce. The program is located in Germany, Belgium, Spain, France, Italy, Netherlands, Portugal, Switzerland, and will soon integrate Ireland and Norway. This proves the graduate expansion of TechShare and confirms its position as a benefactor for IPOs.
Lionel Brodard, CFO of MedXCell SA said: “We look forward to participating in this high-quality program. We want to thank Euronext for this selection which will help us understand the capital market better and prepare for a forthcoming IPO”. Laurent Zbinden, CEO of MedXCell SA, added: “We are thrilled to join TechShare. We envisage an IPO in the future to enhance and accelerate our mission to develop affordable and accessible cellular therapies to patients”.

About MedXCell

MedXCell SA is a Swiss specialist healthcare group of entities with clinical-stage projects whose mission is to harness the power of cellular therapies to make lives better. It is dedicated to developing and manufacturing innovative off-the-shelf cellular therapies offering state-of-the-art, cost-effective and safe solutions for a wide range of patient needs. The company enjoys a close relationship with academic research, most notably with the Institute for Regenerative Medicine and Biotherapy from the French University Hospital of Montpellier (CHU Montpellier). The MedXCell Group has a workforce currently numbering 25 employees.

Lionel Brodard, CFO

+41 21 963 06 53